Abstract We have found strong evidence for a relation between three high-density lipoprotein (HDL)-binding proteins of 90, 110, and 180 kDa in porcine liver that were detected by ligand blotting. Because HDL-binding proteins with identical molecular masses were detected in human liver, all subsequent experiments were performed with porcine liver proteins. An antiserum raised against a highly purified preparation of the 90-kDa HDL-binding protein, designated 90-PC, showed cross-immunoreactivity with the 110-and 180-kDa HDL-binding proteins. Purified protein preparations of the 90-, 110-, and 180-kDa HDL-binding proteins were obtained and analyzed by polyacrylamide gel electrophoresis with sodium dodecyl sulfate. Under nonreducing conditions these preparations showed protein bands with the expected molecular masses. Reduction of these preparations resulted in protein bands of 90 kDa. Ligand blotting experiments with 125 I-HDL showed protein bands of 90,110, and 180 kDa under nonreducing conditions and a 90-kDa protein band in all three preparations under reducing conditions. Immunoblotting experiments with 90-PC antiserum resulted in a similar pattern. The three protein preparations were then subjected to cyanogen bromide cleavage and the resulting peptides separated on gel. Immunoblotting with the 90-PC antibody revealed a pattern of protein bands that was remarkably similar in all three protein preparations. Immunohistochemical localization studies with the 90-PC antibody showed that the HDL-binding proteins were present both at the borders of the sinusoids as well as within the hepatocellular plates. We conclude that the 180-kDa form is a homodimer of a monomeric HDL-binding protein present in two conformation variants of 90 and 110 kDa. (Arterioscler Thromb. 1994;14:305-312.)
I-HDL showed protein bands of 90,110, and 180 kDa under nonreducing conditions and a 90-kDa protein band in all three preparations under reducing conditions. Immunoblotting experiments with 90-PC antiserum resulted in a similar pattern. The three protein preparations were then subjected to cyanogen bromide cleavage and the resulting peptides separated on gel. Immunoblotting with the 90-PC antibody revealed a pattern of protein bands that was remarkably similar in all three protein preparations. Immunohistochemical localization studies with the 90-PC antibody showed that the HDL-binding proteins were present both at the borders of the sinusoids as well as within the hepatocellular plates. We conclude that the 180-kDa form is a homodimer of a monomeric HDL-binding protein present in two conformation variants of 90 and 110 tion between plasma levels of high-density lipoprotein (HDL) and the incidence of atherosclerosis. Therefore, HDL is believed to possess antiatherogenic properties. 12 This concept is supported by studies with laboratory animals, in which the administration of HDL has been shown to have antiatherogenic effects. 34 Very strong evidence comes from observations of transgenic mice that overexpress human apolipoprotein (apo) A-I. These animals have higher levels of HDL in their plasma, and the development of atherosclerosis induced by a hypercholesterolemic diet is inhibited in comparison to control animals. 5 The antiatherogenicity of HDL probably resides in its capability to transfer cholesterol from peripheral tissues to the liver for excretion, a process called reverse cholesterol transport. 6 ' 7 Detailed knowledge about the functioning of the reverse cholesterol transport pathway and about the factors that regulate and affect it is still largely lacking.
There are two processes in this pathway in which HDL-binding proteins may be involved. These are the efflux of cholesterol from peripheral cells to HDL and the uptake of HDL particles or HDL cholesterol by the liver. Controversy exists about the mechanism by which HDL is able to take up cholesterol from cells in peripheral tissues. 8 Some authors do not find positive evidence for a relation between HDL binding and cholesterol efflux from cells to HDL particles. 9 -10 Graham and Oram 11 and Oram and coworkers, 12 however, describe an HDL-binding protein of 110 kDa that has been shown to be involved in cholesterol efflux. Recently, a cDNA clone that probably encodes this protein has been isolated. 13 In the liver, HDL-binding proteins have also been described. Tozuka and Fidge 14 have found two HDLbinding proteins of 100 and 120 kDa in rat liver. In the human hepatoma cell line Hep3B, HDL-binding proteins of 60,100, and 210 kDa have been described. 15 We have characterized two HDL-binding proteins of 90 and 180 kDa in porcine liver. We have also found evidence for two HDL-binding proteins of 110 and 130 kDa in porcine liver, which appear to be present in minor quantities. 16 In this article we describe a structural relation between the 90-, 110-, and 180-kDa proteins.
Methods
Plasma from healthy human volunteers was used for isolation of low-density lipoproteins (LDLs; d=1.019 to 1.063 g/mL) and HDLs (rf= 1.063 to 1.21 g/mL) by sequential ultracentrifugation. 17 HDL was subjected to heparin-Sepharose affinity chromatography to remove apoB/E-containing particles. 18 Analysis of lipoprotein preparations was performed by electrophoresis on polyacrylamide gels in the presence of sodium dodecyl sulfate (SDS-PAGE) according to Laemmli. 19 In the HDL preparations, apoA-I, apoA-II, and apoC's were detected; no apoE was present. In the LDL preparations, apoB-100 appeared to be the only protein constituent. HDL was radiolabeled with 125 1% was free. The protein-bound radioactivity was present in apoA-I (60% to 65%), apoA-II (23% to 25%), and apoC (very small amounts). Specific activities were approximately 300 cpm/ng protein.
HDL-Binding Assay
HDL-binding proteins were studied in a ligand-blot assay as described. 16 In brief, protein fractions were subjected to SDS-PAGE and electrophoretically transferred onto nitrocellulose membranes (0.45 fim, Schleicher & Schuell). 21 These membranes were incubated with blocking buffer (10 
Solubilization of Liver Proteins
All operations were carried out at 0°C to 4°C. Porcine livers obtained from the Department of Experimental Cardiology, Erasmus University Rotterdam, were collected on ice immediately after death of the animal, cut into small pieces, and stored at -70°C. The pigs weighed approximately 60 kg and were 3 to 4 months old. For protein solubilization, a plasma membrane-enriched fraction was prepared essentially according to Schneider et al. 22 Liver tissue (100 g) was minced with surgical blades and homogenized with an Ultra-Turrax TP 18-10 in 200 mL of 10 mmol/L Tris-HCl, pH 8.0; 150 mmol/L NaCl; 1 mmol/L benzamidine; 0.5 mmol/L EDTA; and 1 mmol/L phenylmethylsulfonyl fluoride. Tissue debris was removed by centrifugation (10 minutes, 1350g). The supernatant was centrifuged (60 minutes, 100 OOOg) and the pellet resuspended in 120 mL homogenization buffer containing 1% (vol/vol) Triton X-100 by aspiration with a 22-gauge needle. The suspension was stirred for 10 minutes and slowly diluted 10 times in 10 mmol/L Tris-HCl, pH 8.0; 2 mmol/L CaCl 2 ; and 1% (vol/vol) Triton X-100. After removal of the paniculate material by centrifugation (30 minutes, 20 OOOg), a clear supernatant was obtained.
DEAE-Cellulose Chromatography
The solubilized fraction was applied to a DEAE-cellulose column (2.4x10 cm; DE-52, Whatman) at a flow rate of 30 mL/h. The column was washed with 10 mmol/L Tris-HCl, pH 8.0; 2 mmol/L CaCl 2 ; and 15 mmol/L CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-l-propanesulfonate). Elution was performed with the wash buffer containing increasing concentrations of sodium chloride.
Concanavalin A (ConA) Chromatography
DEAE-cellulose fractions containing HDL-binding activity were pooled and dialyzed against 20 mmol/L sodium phosphate, pH 6.8; 0.25 mmol/L CaCl 2 ; 0.25 mmol/L MnSO 4 ; and 10 mmol/L NaCl (ConA buffer). ConA-Sepharose 4B (Sigma) was added to these fractions. The reaction was allowed to proceed overnight at 4°C under gentle agitation. The gel was transferred to a column and washed with ConA buffer containing 1 mol/L NaCl and eluted with ConA buffer containing 0.5 mol/L NaCl and 1 mol/L methyl-a-D-glucopyranoside.
Preparative Continuous Elution Electrophoresis
Protein samples were run on a Bio-Rad model 491 Prep Cell apparatus, following the manufacturer's instructions. Typically, in the first run approximately 15 mg protein was applied on a 5.5% polyacrylamide gel in the presence of SDS. Fractions of 10 mL were collected. These fractions were lyophilized and tested in the HDL-binding assay. Fractions containing one of the HDL-binding proteins were pooled and subjected to a second round of continuous elution electrophoresis. In this second round, approximately 1 mg protein was applied to the gel. The composition of the gel was varied according to the molecular mass of the protein of interest (eg, 7% for the 90-kDa protein). To achieve optimal separation, subsequent runs with small variations in percent acrylamide were sometimes required if proteins of approximately the same molecular masses were present in the preparation.
Cyanogen Bromide (CNBr) Fragmentation
Chemical cleavage with CNBr was performed essentially according to Matsudaira. 23 Protein samples for CNBr fragmentation were dialyzed against 10 mmol/L NH 4 HCO 3 and lyophilized. Aliquots (200 fiL) were added from an 80 mg/mL CNBr solution in 70% formic acid and incubated at room temperature in the dark under nitrogen gas. The sample was diluted 10 times with water and lyophilized. Sample buffer was added, and the fragments were run on a 16% Tricine (Ntris(hydroxymethyl)methylglycine)-SDS-PAGE gel according to Schagger and Von Jagow.
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Antisera
Antibodies to HDL or HDL-binding proteins were prepared by standard techniques. 25 In brief, 50 /xg protein was applied to an SDS-PAGE gel and electrophoretically transferred onto nitrocellulose membranes. Small strips of these membranes with the protein of interest were cut out and dissolved in dimethyl sulfoxide. Incomplete Freund's adjuvant (1 mL) was added. A New Zealand White rabbit was injected subcutaneously with this mixture. Two boosters of the same mixture were given at intervals of 28 days. Ten days after the last injection, the blood was collected and the serum obtained by centrifugation at 1300g after clotting. All animals were cared for in compliance with the Guidelines of the Ethics Committee on the Use of Laboratory Animals of the Erasmus University Rotterdam (protocol No. 132.91.52) and the European Committee Standards on the care and use of laboratory animals (Ministry of Welfare, Health and Cultural Affairs, the Netherlands).
Immunoblotting
Protein samples were subjected to SDS-PAGE and electrophoretically transferred onto nitrocellulose membranes, which were incubated with blocking buffer (without LDL) containing 0.05% (vol/vol) Tween-20 as described for the ligand-blot assay procedure, followed by a 2-hour incubation with blocking buffer containing 0.05% (vol/vol) Tween-20 and anti-HDL-binding protein antiserum (dilution, 1:1000). Alkaline phosphatase-conjugated goat F(ab') 2 anti-rabbit immunoglobulins (Tago, Inc, Burlingame, Calif) were used as the secondary antibody. Reactive proteins were visualized with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium. Control incubations were performed either using preimmune serum or omitting the first antibody. Virtually no protein bands were visible in these control experiments, unless indicated otherwise.
Elution of Specific Antibodies From Nitrocellulose Membranes
Protein samples were subjected to SDS-PAGE and electrophoretically transferred onto nitrocellulose membranes. These membranes were subjected to the immunoblotting procedure. For incubation with the secondary antibody and subsequent visualization, a vertical strip cut from each nitrocellulose membrane was used. With this strip as a reference, horizontal strips were cut from the unstained nitrocellulose membrane containing immunoreactive proteins of 90 and 180 kDa. The antibodies were eluted by a procedure adapted from Smith Proteins were solubilized from a plasma membrane-enriched fraction of either porcine or human liver and applied to DEAE-cellulose. 16 Elution was performed with a discontinuous salt gradient. Fractions containing HDL-binding activity were applied to concanavalin A (ConA)-Sepharose. Retained proteins were eluted by methyl-a-o-glucopyranoside (ConAfraction). ConA-fraction preparations were analyzed in the HDL-binding assay as described in "Methods." Proteins were run on a 6.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel under nonreducing conditions and blotted onto nitrocellulose membranes. In each lane, 100 ng protein was applied, and the filters were incubated with 
Immunohistochemistry
The porcine liver was fixed and prepared for ultracryotome sectioning as described. 27 Semithin cryosections (0.5 to 1.0 fim) were incubated with a protein A-Sepharose CL-4B (Pharmacia)-purified immunoglobulin G fraction of polyclonal antibodies against HDL-binding proteins (dilution, 1:10) for 1 hour at room temperature in a humid incubator. Antigenantibody complexes were visualized with fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulins (Nordic, Tilburg, the Netherlands; diluted 1:80 and incubated at room temperature for 1 hour in a humid incubator) and studied by fluorescence microscopy.
Results
Membrane proteins from porcine liver were applied to DEAE-cellulose and eluted with a discontinuous salt gradient (50, 250, and 1000 mmol/L NaCl) as described. 16 Fractions containing HDL-binding proteins (the 250 mmol/L-NaCl eluate), as established in the HDL-binding assay, were pooled and dialyzed against ConA buffer as described in "Methods" and subjected to ConA-Sepharose chromatography. Retained proteins were eluted with methyl-a-D-glucopyranoside. Protein recoveries were approximately 12% after DEAE-cellulose and 3% after ConA-Sepharose chromatography. This protein preparation, which is referred to as the ConA fraction, appeared to contain two major HDLbinding proteins of 90 and 180 kDa and two less prominent ones of 110 and 130 kDa (Fig 1) . For comparison, a ConA fraction from human liver was prepared in exactly the same way. This fraction showed HDL-binding proteins of 90, 110, and 180 kDa in approximately equal amounts (Fig 1) . Because of easy Proteins from the concanavalin A fraction of porcine liver were subjected to preparative continuous elution electrophoresis. In the first run, 15 mg protein was applied without reducing agents to a 5.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Eluted proteins were collected in 10-mL fractions. Small samples of consecutive fractions were applied to a 5.5% SDS-PAGE slab gel and run under nonreducing conditions, and proteins were stained with Coomassie Brilliant Blue (top; lane C, starting material; lanes 1 through 8, eight consecutive fractions). Fractions containing proteins of approximately 90 kDa (including the 90-kDa HDL-binding protein as tested in the HDL-binding assay) were pooled and run on a 7% SDS-PAGE gel under nonreducing conditions by preparative continuous elution electrophoresis. Eluted proteins were collected in consecutive 2-mL fractions, of which 20-ju.L samples were run on a 7% SDS-PAGE slab gel under nonreducing conditions, and proteins were stained with Coomassie Brilliant Blue (bottom). Lanes 1 through 8 show eight consecutive fractions, including those containing the 90-kDa HDL-binding protein. Fractions were tested for the presence of the 90-kDa HDL-binding protein in the HDL-binding assay (results not shown). Those fractions in which the 90-kDa HDL-binding protein was present in an apparently homogenous form (lanes 5 through 7) were pooled and concentrated by lyophilization. Lane on the right (P) is a 5-/ng sample from this preparation run on a 7% SDS-PAGE slab gel under nonreducing conditions; proteins were again stained with Coomassie Brilliant Blue.
availability, we performed all subsequent studies with porcine liver. The ConA fraction was subjected to preparative continuous elution electrophoresis on a Bio-Rad model 491 Prep Cell system. During the first run, fractions of 10 mL were collected. Fig 2, top, shows samples of consecutive fractions containing proteins of increasing molecular mass ranging from approximately 40 to 100 kDa. These fractions were tested for HDLbinding activity in the HDL-binding assay. Those fractions containing the 90-kDa HDL-binding protein were pooled and subjected to another run of continuous elution electrophoresis while the composition of the gel was varied to obtain optimal separation in the range of molecular masses of proteins still present in the applied preparation. Those fractions in which the 90-kDa HDLbinding protein was present in an apparently homogeneous form were pooled and used for further study (Fig  2, bottom, right lane) . From 100 g liver tissue, approximately 0.5 mg of purified 90-kDa HDL-binding protein was isolated. This purified fraction was used to develop a high-titer polyclonal antiserum in rabbits. As shown in Fig 3, this antiserum, designated 90-PC, reacted with the purified 90-kDa HDL-binding protein on an immunoblot. 90-PC also recognized a protein band of 90 kDa in the ConA fraction. In addition, an unambiguous crossreaction with protein bands of 110 and 180 kDa was observed in this fraction. Both 110 and 180 kDa are molecular masses of HDL-binding proteins. This crossreactivity of an antiserum raised against a purified preparation of the 90-kDa HDL-binding protein suggests a structural relation between these three proteins.
To evaluate this cross-reactivity, nitrocellulose membranes on which ConA-fraction proteins were blotted were incubated with 90-PC antiserum followed by elution of antibodies from strips of the nitrocellulose membranes cut out at the 90-and 180-kDa positions. These antibody eluates were used in immunoblotting experiments with ConA-fraction proteins (Fig 4) . These experiments showed that antibodies eluted from the 90-kDa as well as those eluted from the 180-kDa position showed cross-reactivity with proteins of 90 and 180 kDa. No protein band was visible at 110 kDa, probably because the amount of 110 kDa protein was below the level of detection.
To investigate the possible relation between the 90-, 110-, and 180-kDa HDL-binding proteins, we prepared purified protein fractions of the 110-and 180-kDa proteins from the ConA fraction, using preparative continuous elution electrophoresis as described above for purification of the 90-kDa protein. However, compared with the 90-kDa HDL-binding protein, the yield of these proteins was much lower (approximately 10 to 25 times). The purified protein preparations were examined on a Coomassie Brilliant Blue-stained SDS-PAGE gel run under either nonreducing or reducing conditions ( Fig  5) . For the 180-kDa protein, a purified preparation of apparent homogeneity was obtained. For the 110-kDa protein, however, only partial purification was achieved. The protein band of 110 kDa on a nonreducing SDS-PAGE gel consisted of three proteins, as became apparent when a sample was run under reducing conditions. Surprisingly, under reducing conditions the 90-as well as the 180-kDa preparation showed a single protein band with an apparent molecular mass of 90 kDa, whereas a protein band of 90 kDa was also present in the 110-kDa preparation. The 90-kDa band in the 110-kDa protein preparation on reducing SDS-PAGE gels may originate from a protein consisting of two subunits with molecular masses of 90 and 20 kDa, respectively. Therefore, a sample of the 110-kDa preparation was run on a gradient gel under reducing conditions to focus on the possible presence of small protein fragments. No protein bands smaller than 90 kDa were detected (results not shown).
HDL-binding capacities of the purified protein fractions (90, 110, and 180 kDa) were examined. As shown in Fig 6, under nonreducing conditions each protein preparation showed HDL-binding activity. Under reducing conditions in all three preparations, HDL-binding activity was present at the 90-kDa position only. In Fig 7, reaction of the three size fractions with 90-PC antiserum is shown under either nonreducing or reducing conditions. Protein bands of 90, 110, and 180 kDa were visible under nonreducing conditions, and only a 90-kDa band was visible in each preparation under reducing conditions.
We subjected the three protein fractions to CNBr cleavage. The samples were run on an AMris(hydroxymethyl)methylglycine-SDS-PAGE gel and blotted onto nitrocellulose. With 90-PC antiserum, immunoblots of the 90-, 110-, and 180-kDa protein fractions were produced (Fig 8) . This resulted in specific patterns of protein bands. These patterns show striking similarities, strongly suggesting that the three preparations consist of the same protein in different conformations.
The newly developed 90-PC antiserum was also applied in an immunohistochemical localization study with porcine liver sections (Fig 9) . This study showed that HDL-binding proteins were present both in the hepatocellular plates as well as at the lining of the sinusoids. These are localization sites that have been previously shown to be specifically labeled with antisera recognizing either the 90-or 180-kDa HDL-binding protein. 16 The reactivity of these antisera was tested with purified preparations of HDL-binding proteins used in this study (Fig 10) . The antiserum directed against the 90-kDa HDL-binding protein reacted with the purified 90-kDa protein preparation under nonreducing conditions but hardly reacted under reducing conditions. The antiserum directed against the 180-kDa HDL-binding protein reacted with the purified 180-kDa protein prep- aration under nonreducing conditions but not under reducing conditions.
Discussion
We have found strong evidence for a relation between three HDL-binding proteins in porcine liver. These proteins have apparent molecular masses of 90,110, and 180 kDa as determined by SDS-PAGE under nonreducing conditions.
The 180-kDa protein can be reduced, resulting in a single protein band of 90 kDa that still shows HDLbinding activity. Both the unreduced 180-kDa protein as well as the reduced 90-kDa protein resulting from reduction of the 180-kDa protein are recognized by the 90-PC antiserum that was raised against the purified 90-kDa HDL-binding protein. Antibodies from 90-PC antiserum that eluted from the 180-kDa protein on nitrocellulose membranes after immunoblotting crossreacted with a 90-kDa protein. Also, antibodies eluted from the 90-kDa protein cross-reacted with a 180-kDa protein. Therefore, 90-PC antiserum is not a mixture of antibodies reacting with either the 90-or 180-kDa protein, and the 90-PC antibodies have genuine crossreactivity with these two proteins. These results suggest that the 180-kDa protein is a dimer of the 90-kDa protein. We produced CNBr cleavage maps with antibody 90-PC (Fig 8) . Protein fragment bands appearing in both samples show a strikingly similar pattern, suggesting that the 180-kDa protein consists of two identical 90-kDa subunits; ie, that the 180-kDa form is a homodimer of the 90-kDa HDL-binding protein. In the purification procedure, the yield of 90-kDa HDL-binding protein is higher than that of the 180-kDa HDLbinding protein. Therefore, we used a larger amount of the 90-kDa protein preparation than of the 180-kDa protein preparation. As a consequence, the faintest bands in the 90-kDa sample (Fig 8, lane 1) are not visible in the 180-kDa sample (Fig 8, lane 3) . However, no protein fragment bands were detected in the 180-kDa sample that were absent in the 90-kDa sample. This would be highly unlikely if these two preparations had come from two different proteins or if one preparation had contained an additional protein.
A partially purified preparation of the 110-kDa HDL-binding protein also showed a 90-kDa protein band after reduction followed by SDS-PAGE, which was shown to bind HDL and to cross-react with 90-PC antiserum. In a protein-stained gel, no protein bands smaller than 90 kDa were observed under reducing conditions. Thus, the 110-kDa form apparently does not consist of two subunits of 90 and 20 kDa. The 110-kDa protein is probably a protein conformation variant of the 90-kDa protein that has a running pattern in an SDS-PAGE system under nonreducing conditions that leads to a calculated mass of 110 kDa. This may be caused by an internal disulfide bond. Reduction allows the protein to run at a 90-kDa position. A CNBr map of the 110-kDa HDL-binding protein appears to have given a pattern identical to that of the 90-kDa HDLbinding protein, leading to the conclusion that the 110-kDa protein is an alternative conformation of the 90-kDa HDL-binding protein.
The newly developed 90-PC antiserum that was raised against the 90-kDa HDL-binding protein and that cross-reacted with 110-and 180-kDa HDL-binding proteins was tested in a histochemical study. We have previously shown that the 90-kDa HDL-binding protein is localized within the hepatocellular plates, whereas the 180-kDa HDL-binding protein is situated at the lining of the sinusoids. 16 The cross-reactivity of our newly developed 90-PC antiserum should result in a combination of these localization sites. This anticipation proved to be correct, as shown in Fig 7. We cannot readily attribute an extra signal to the cross-reactivity In a previous study, we described monospecific antisera raised against the 90-and 180-kDa HDL-binding proteins. 16 This led us to assume that there was no simple relation between the 90-and 180-kDa proteins. We tested these antisera with purified HDL-binding protein preparations as described in immunoblotting experiments in this study (Fig 10) . On the basis of the results, we can make the following conclusions. (1) The monospecific 180-kDa antiserum apparently recognizes a structural determinant that is present only in the dimeric form for the following reasons: (a) The antiserum shows no cross-immunoreactivity with the purified 90-or 110-kDa HDL-binding protein preparations under either nonreducing or reducing conditions, (b) The antiserum reacts with the purified 180-kDa HDL-bind-ing protein under nonreducing conditions but not with the 90-kDa protein band, that results of reduction of the purified 180-kDa HDL-binding protein. (2) Thus, the antiserum recognizes the dimeric but not the monomeric form of the protein, which implies that the structural determinant on the dimeric form has induced a dominant immunogenic response.
The monospecificity of the previously reported antiserum directed against the 90-kDa HDL-binding protein 16 is puzzling. This antiserum recognizes purified 90-kDa HDL-binding protein preparations under nonreducing conditions but very poorly under reducing conditions. Purified 110-or 180-kDa protein preparations are not recognized by the antiserum under either nonreducing or reducing conditions (results not shown). An explanation could be that this antiserum reacts with a unique determinant of nonreduced 90-kDa HDLbinding protein on nitrocellulose membranes. This hypothesis is supported by the following observations. During preparation of this antiserum, we found that the protein was not very immunogenic. When preparations of electroeluted protein in solution were used to produce antisera, no immunogenic response was evoked in the rabbits. Only when we used preparations obtained by separating proteins on SDS-PAGE, transferring them to nitrocellulose membranes, and solubilizing the nitrocellulose in dimethyl sulfoxide, did we succeed in raising an antiserum. The protein probably has a defined conformation as a result of these procedures, which exposes the structural domain that evokes an immune response. As a result, the antiserum reacts preferentially with this structural domain. This might also explain why our attempts to immunoprecipitate the protein from solution with this antiserum were unsuccessful, in contrast to similar experiments with the monospecific antiserum directed against the 180-kDa HDL-binding protein. 16 In the latter case, the amount of immunoprecipitated protein was high enough to show that it had HDL-binding activity. For the monospecific antiserum to the 90-kDa protein, however, we have no actual proof that it is indeed directed against an HDLbinding protein, and therefore, we cannot exclude the possibility that it recognizes a contaminating protein in the purified 90-kDa protein fraction. Although the localization pattern in the hepatocellular plates in the immunohistochemical studies with this antiserum resembles part of the pattern for the newly developed 90-PC antiserum, it does not give conclusive evidence that the two antisera recognize the same protein. This evidence will eventually come from isolation and expression of cDNA clones that encode the HDL-binding protein, followed by irnrnunochernica! studies.
It is surprising that two antisera raised against purified preparations of the same protein have different characteristics. The 90-PC antiserum described in this study can also be raised against proteins eluted from nitrocellulose. However, the immunization procedure differs at two steps from the procedure used in our previous study. 16 First, the amount of protein used for immunization was probably much higher for 90-PC antiserum than for the antiserum directed against the 90-kDa HDL-binding protein in our previous study. In the latter case, we overestimated the amount of protein, since we now know that the electroelution procedure in the final purification step results in a very low recovery compared with the preparative continuous elution electrophoresis step in the present study. Second, the immunization scheme is different. Two boosters were given at intervals of 28 days, whereas in the previous study boosters were given at 15 and 25 days after the first injection. This timing may be crucial, since in the test with ConA-fraction proteins the cross-reactivity of 90-PC antiserum after the first booster with the 180-kDa HDL-binding protein was rather weak, whereas cross-reactivity with the 110-kDa HDL-binding protein became apparent only after the second booster. This disparity cannot be attributed to differences in protein preparation, since the same preparation was used for the immunization and subsequent boosts.
Several attempts have been made to achieve immunoprecipitation with the 90-PC antiserum. The amount of immunoprecipitated protein appeared to be too low to allow detection of HDL-binding activity in the HDLbinding assay. However, in cultured porcine hepatocytes labeled with [ The three related HDL-binding proteins from porcine liver that we describe in this study are also present in human liver (Fig 1) . In Hep3B cells, a human hepatoma cell line, HDL-binding proteins of 60, 100, and 210 kDa have been reported. 15 When gels are run under reducing conditions, the 210-kDa HDL-binding signal disappears while the 100-kDa HDL-binding signal intensifies. Therefore, a monomer-dimer relation between the 100-and 210-kDa HDL-binding proteins has been suggested. These proteins probably resemble the 90-or 110-and 180-kDa HDL-binding proteins we describe in this study.
Graham and Oram 11 have described an HDL-binding protein of 110 kDa in a number of cultured cells. Recently, Oram and coworkers 12 have isolated a cDNA clone that probably encodes this protein. 13 Although we have found a 110-kDa HDL-binding protein in both human and porcine liver, these two proteins are probably not identical. Although Graham and Oram 11 have found a 110-kDa HDL-binding protein in a solubilized membrane protein preparation, we have detected HDL-binding proteins of 90 and 180 kDa in a preparation that is obtained in virtually the same way. The 110-kDa HDL-binding protein in our studies is detectable only after further purification. In contrast, Oram and coworkers have never reported the detection of 90-or 180-kDa HDL-binding proteins. Moreover, Graham and Oram 11 have found no change in relative migration of the 110-kDa protein on SDS-PAGE after reduction, whereas in this study we show that the 110-kDa HDLbinding protein from liver migrates at the 90-kDa position under reducing conditions. Probably, the 110-kDa protein that has been studied by Oram and coworkers, described mainly in peripheral cells like bovine aortic endothelial cells and mouse macrophages (J774), is involved in cholesterol efflux from cells to HDL, as indeed is strongly suggested by a number of studies from this group. 28 The proteins we describe in liver are more likely to be involved in the uptake of HDL cholesterol by the liver. Therefore, there is probably also a functional difference between these proteins.
Tozuka and Fidge 14 have found HDL-binding proteins of 100 and 120 kDa in rat liver. Because estima-tions of molecular mass by SDS-PAGE are related to protein standards, deviations can occur between different laboratories. Therefore, the proteins found by Tozuka and Fidge could be homologues of the 90-and 110-kDa HDL-binding proteins in this study. A comparison between nonreducing and reducing conditions has revealed that the 100 -kDa protein is not affected by reduction, which agrees with the results on the 90-kDa HDL-binding protein in our study. In contrast, the 120-kDa protein shows a strongly diminished HDLbinding activity but no change in mobility on SDS-PAGE after reduction, which contrasts with our observations on the 110-kDa protein. At the moment, it is not clear whether there is a relation between these proteins.
Antisera raised against porcine HDL-binding proteins do not cross-react with human proteins. This was tested both in immunoblotting experiments and immunohistochemical studies (results not shown), which greatly impairs the possibility of performing physiological studies in hepatoma cell culture systems, since a system of porcine origin is unavailable. These studies are nevertheless essential for evaluation of the physiological function of the HDL-binding proteins described. At the moment, we are preparing experiments with primary hepatocytes derived from pigs.
Some speculation with regard to the functional differences between the HDL-binding proteins can be made on the basis of their immunohistochemically determined localizations. We found HDL-binding proteins localized both at the lining of the sinusoids and in the hepatocellular plates. The proteins localized at the sinusoids are possibly involved in cellular uptake of HDL. The proteins localized within the hepatocellular plates may be involved in retroendocytosis or metabolism of HDL. Another possibility is that the 180-kDa HDL-binding protein present at the sinusoidal borders binds HDL to facilitate cholesterol influx to liver cells and/or interaction with hepatic lipase, which has the same localization. 29 The 90-kDa HDL-binding protein may be an intracellular metabolic intermediate. Because no specific localization of the 110-kDa HDLbinding protein has been determined, speculation on its functional role seems inappropriate. Confirmation of these speculative models, as well as establishment of the role of individual HDL-binding proteins in hepatic HDL metabolism, clearly awaits further research.
